| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 48 | 2023 | 119 | 19.360 |
Why?
|
| Students, Medical | 17 | 2023 | 384 | 5.450 |
Why?
|
| Curriculum | 22 | 2024 | 539 | 5.300 |
Why?
|
| Internship and Residency | 24 | 2023 | 1004 | 4.020 |
Why?
|
| Clinical Clerkship | 9 | 2018 | 116 | 3.670 |
Why?
|
| Program Evaluation | 10 | 2020 | 297 | 2.010 |
Why?
|
| Clinical Competence | 12 | 2023 | 751 | 2.000 |
Why?
|
| Education, Medical, Undergraduate | 6 | 2019 | 160 | 2.000 |
Why?
|
| Brachytherapy | 5 | 2023 | 119 | 1.900 |
Why?
|
| Needs Assessment | 6 | 2021 | 154 | 1.830 |
Why?
|
| Career Choice | 7 | 2020 | 139 | 1.800 |
Why?
|
| Chemoradiotherapy | 6 | 2020 | 301 | 1.790 |
Why?
|
| Medical Oncology | 5 | 2024 | 359 | 1.620 |
Why?
|
| Surveys and Questionnaires | 24 | 2022 | 2501 | 1.580 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2020 | 176 | 1.560 |
Why?
|
| Interprofessional Relations | 3 | 2021 | 121 | 1.540 |
Why?
|
| Education, Medical, Graduate | 7 | 2023 | 369 | 1.330 |
Why?
|
| Patient Education as Topic | 4 | 2023 | 351 | 1.300 |
Why?
|
| Educational Measurement | 8 | 2019 | 225 | 1.270 |
Why?
|
| Radiation Oncologists | 5 | 2022 | 13 | 1.230 |
Why?
|
| Reading | 2 | 2019 | 30 | 1.210 |
Why?
|
| Radiotherapy, Conformal | 3 | 2020 | 83 | 1.190 |
Why?
|
| Health Literacy | 3 | 2023 | 70 | 1.160 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2023 | 275 | 1.120 |
Why?
|
| Humans | 83 | 2024 | 86617 | 1.070 |
Why?
|
| School Admission Criteria | 2 | 2016 | 23 | 1.030 |
Why?
|
| Education, Nursing | 2 | 2021 | 10 | 0.990 |
Why?
|
| Schools, Medical | 3 | 2023 | 123 | 0.990 |
Why?
|
| United States | 23 | 2023 | 6665 | 0.990 |
Why?
|
| Radiotherapy Dosage | 7 | 2023 | 468 | 0.970 |
Why?
|
| Internet | 5 | 2018 | 312 | 0.920 |
Why?
|
| Neoplasms | 5 | 2023 | 2898 | 0.870 |
Why?
|
| Interdisciplinary Studies | 2 | 2019 | 20 | 0.850 |
Why?
|
| Radiotherapy, Image-Guided | 3 | 2021 | 56 | 0.840 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2020 | 173 | 0.810 |
Why?
|
| Integrative Medicine | 1 | 2021 | 8 | 0.800 |
Why?
|
| Medical Staff | 1 | 2021 | 10 | 0.790 |
Why?
|
| Interdisciplinary Communication | 2 | 2021 | 130 | 0.780 |
Why?
|
| Virtual Reality | 1 | 2020 | 21 | 0.770 |
Why?
|
| Complementary Therapies | 1 | 2021 | 54 | 0.760 |
Why?
|
| Mentoring | 1 | 2021 | 30 | 0.740 |
Why?
|
| Patient Care Team | 2 | 2021 | 280 | 0.740 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 1169 | 0.740 |
Why?
|
| Congresses as Topic | 1 | 2020 | 116 | 0.730 |
Why?
|
| Radiosurgery | 3 | 2013 | 272 | 0.720 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.660 |
Why?
|
| Physicians | 3 | 2024 | 673 | 0.650 |
Why?
|
| Female | 34 | 2023 | 44509 | 0.630 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2020 | 1075 | 0.620 |
Why?
|
| Elbow Joint | 2 | 2008 | 34 | 0.590 |
Why?
|
| Male | 32 | 2021 | 40958 | 0.590 |
Why?
|
| Range of Motion, Articular | 2 | 2008 | 154 | 0.590 |
Why?
|
| Simulation Training | 1 | 2018 | 88 | 0.580 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 202 | 0.580 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2016 | 47 | 0.570 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 379 | 0.560 |
Why?
|
| Pamphlets | 1 | 2015 | 14 | 0.520 |
Why?
|
| Teaching | 1 | 2016 | 147 | 0.520 |
Why?
|
| Fluorouracil | 3 | 2016 | 556 | 0.510 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2019 | 1075 | 0.510 |
Why?
|
| Pediatrics | 1 | 2018 | 344 | 0.480 |
Why?
|
| Adult | 20 | 2021 | 25640 | 0.480 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 508 | 0.470 |
Why?
|
| CA-19-9 Antigen | 1 | 2012 | 11 | 0.440 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 2262 | 0.430 |
Why?
|
| Pilot Projects | 4 | 2020 | 839 | 0.430 |
Why?
|
| Carcinoma | 2 | 2012 | 436 | 0.430 |
Why?
|
| Prostatic Neoplasms | 3 | 2021 | 1721 | 0.420 |
Why?
|
| Research | 2 | 2013 | 253 | 0.420 |
Why?
|
| Induction Chemotherapy | 1 | 2012 | 147 | 0.410 |
Why?
|
| Program Development | 4 | 2021 | 124 | 0.370 |
Why?
|
| Young Adult | 7 | 2019 | 5974 | 0.350 |
Why?
|
| Cross-Sectional Studies | 7 | 2022 | 1621 | 0.350 |
Why?
|
| Incidental Findings | 2 | 2020 | 95 | 0.350 |
Why?
|
| Comprehension | 3 | 2023 | 79 | 0.350 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 426 | 0.350 |
Why?
|
| Lymphatic Metastasis | 3 | 2020 | 481 | 0.340 |
Why?
|
| Consensus | 3 | 2022 | 335 | 0.340 |
Why?
|
| Canada | 4 | 2022 | 204 | 0.320 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 621 | 0.320 |
Why?
|
| Ulna | 1 | 2007 | 13 | 0.300 |
Why?
|
| Neoplasm Staging | 6 | 2021 | 1937 | 0.300 |
Why?
|
| Humerus | 1 | 2007 | 31 | 0.300 |
Why?
|
| Education, Medical | 2 | 2024 | 233 | 0.290 |
Why?
|
| Overweight | 1 | 2008 | 118 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 645 | 0.290 |
Why?
|
| Aged | 11 | 2021 | 18402 | 0.280 |
Why?
|
| Data Collection | 3 | 2018 | 372 | 0.280 |
Why?
|
| Middle Aged | 14 | 2021 | 25017 | 0.250 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 1464 | 0.250 |
Why?
|
| Body Mass Index | 1 | 2008 | 770 | 0.240 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 763 | 0.240 |
Why?
|
| Child | 8 | 2021 | 6926 | 0.240 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 291 | 0.240 |
Why?
|
| Organs at Risk | 2 | 2020 | 41 | 0.230 |
Why?
|
| Quality of Life | 2 | 2021 | 1583 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2022 | 80 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 860 | 0.210 |
Why?
|
| Teaching Rounds | 2 | 2020 | 24 | 0.210 |
Why?
|
| Genital Neoplasms, Female | 1 | 2023 | 107 | 0.200 |
Why?
|
| Chi-Square Distribution | 2 | 2020 | 364 | 0.200 |
Why?
|
| Chicago | 2 | 2018 | 1379 | 0.200 |
Why?
|
| Faculty, Medical | 2 | 2020 | 178 | 0.200 |
Why?
|
| Controlled Before-After Studies | 1 | 2021 | 3 | 0.200 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 10 | 0.200 |
Why?
|
| Second-Look Surgery | 1 | 2020 | 4 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2021 | 2767 | 0.200 |
Why?
|
| Hemoglobin A | 1 | 2020 | 8 | 0.200 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 3 | 0.200 |
Why?
|
| Academies and Institutes | 1 | 2021 | 31 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2021 | 8477 | 0.200 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 468 | 0.190 |
Why?
|
| Professional Role | 1 | 2021 | 41 | 0.190 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.190 |
Why?
|
| Radiation Dosage | 1 | 2021 | 227 | 0.190 |
Why?
|
| Mentors | 2 | 2019 | 76 | 0.190 |
Why?
|
| Feedback | 1 | 2021 | 133 | 0.190 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 12 | 0.190 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 16 | 0.190 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 16 | 0.190 |
Why?
|
| Professionalism | 1 | 2020 | 24 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6501 | 0.180 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 38 | 0.180 |
Why?
|
| Smartphone | 1 | 2020 | 36 | 0.180 |
Why?
|
| Treatment Outcome | 6 | 2017 | 7990 | 0.180 |
Why?
|
| Pandemics | 2 | 2023 | 740 | 0.180 |
Why?
|
| Learning | 1 | 2023 | 280 | 0.180 |
Why?
|
| Pain Management | 1 | 2021 | 127 | 0.180 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 37 | 0.180 |
Why?
|
| Qualitative Research | 1 | 2021 | 256 | 0.180 |
Why?
|
| Self Care | 1 | 2021 | 164 | 0.180 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 174 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 3636 | 0.180 |
Why?
|
| Hysterectomy | 1 | 2020 | 146 | 0.180 |
Why?
|
| Mediastinum | 1 | 2019 | 46 | 0.170 |
Why?
|
| Safety | 1 | 2020 | 152 | 0.170 |
Why?
|
| Time Factors | 5 | 2020 | 5209 | 0.170 |
Why?
|
| Models, Educational | 1 | 2019 | 50 | 0.170 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 32 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 552 | 0.170 |
Why?
|
| Self-Assessment | 1 | 2018 | 47 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 86 | 0.170 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.160 |
Why?
|
| Survival Rate | 3 | 2012 | 1860 | 0.160 |
Why?
|
| Manikins | 1 | 2018 | 41 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 1313 | 0.160 |
Why?
|
| Patient Simulation | 1 | 2018 | 42 | 0.160 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2019 | 138 | 0.160 |
Why?
|
| Postoperative Care | 1 | 2019 | 221 | 0.160 |
Why?
|
| Workload | 1 | 2019 | 128 | 0.160 |
Why?
|
| Computer-Assisted Instruction | 1 | 2018 | 43 | 0.160 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 429 | 0.160 |
Why?
|
| Informed Consent | 1 | 2020 | 266 | 0.160 |
Why?
|
| Hospitals, Teaching | 2 | 2019 | 115 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2020 | 306 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 353 | 0.150 |
Why?
|
| Universities | 1 | 2018 | 135 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 441 | 0.150 |
Why?
|
| Pneumonectomy | 1 | 2019 | 196 | 0.150 |
Why?
|
| Medical Illustration | 1 | 2016 | 16 | 0.150 |
Why?
|
| Radiation Injuries | 2 | 2016 | 155 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2021 | 3611 | 0.150 |
Why?
|
| Endosonography | 1 | 2017 | 96 | 0.150 |
Why?
|
| Leukopenia | 1 | 2016 | 65 | 0.140 |
Why?
|
| Job Satisfaction | 1 | 2017 | 73 | 0.140 |
Why?
|
| General Surgery | 1 | 2019 | 228 | 0.140 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 30 | 0.140 |
Why?
|
| Capecitabine | 2 | 2016 | 96 | 0.140 |
Why?
|
| Bronchi | 1 | 2017 | 229 | 0.140 |
Why?
|
| Pelvic Bones | 1 | 2016 | 44 | 0.140 |
Why?
|
| Texas | 1 | 2016 | 101 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 426 | 0.140 |
Why?
|
| Adolescent | 5 | 2021 | 8979 | 0.140 |
Why?
|
| Radiation, Ionizing | 2 | 2014 | 121 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 257 | 0.140 |
Why?
|
| Biomechanical Phenomena | 2 | 2008 | 457 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 392 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2019 | 530 | 0.130 |
Why?
|
| Societies, Medical | 2 | 2019 | 572 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 267 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 183 | 0.130 |
Why?
|
| Erythrocyte Transfusion | 2 | 2010 | 60 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2012 | 188 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2016 | 435 | 0.130 |
Why?
|
| Radiotherapy | 1 | 2016 | 328 | 0.120 |
Why?
|
| Esophagitis | 1 | 2014 | 42 | 0.120 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 2887 | 0.120 |
Why?
|
| Boston | 1 | 2014 | 33 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 94 | 0.120 |
Why?
|
| Job Application | 1 | 2013 | 8 | 0.120 |
Why?
|
| Consumer Behavior | 1 | 2014 | 29 | 0.120 |
Why?
|
| RNA Helicases | 1 | 2014 | 35 | 0.120 |
Why?
|
| Personnel Selection | 1 | 2014 | 59 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 62 | 0.120 |
Why?
|
| Self Concept | 1 | 2014 | 133 | 0.110 |
Why?
|
| Skin | 1 | 2016 | 554 | 0.110 |
Why?
|
| Sirolimus | 1 | 2014 | 169 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 1204 | 0.110 |
Why?
|
| Social Networking | 1 | 2013 | 75 | 0.110 |
Why?
|
| Metalloporphyrins | 1 | 2012 | 26 | 0.110 |
Why?
|
| Fatigue | 1 | 2013 | 174 | 0.110 |
Why?
|
| Platinum | 1 | 2012 | 63 | 0.110 |
Why?
|
| Hydroxyurea | 1 | 2012 | 239 | 0.110 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2013 | 80 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 269 | 0.110 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1991 | 0.100 |
Why?
|
| Cell Survival | 1 | 2014 | 969 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2601 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2012 | 237 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2012 | 439 | 0.100 |
Why?
|
| Remission Induction | 1 | 2012 | 722 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2014 | 428 | 0.100 |
Why?
|
| Genetic Therapy | 1 | 2012 | 342 | 0.090 |
Why?
|
| Exhalation | 1 | 2010 | 7 | 0.090 |
Why?
|
| Hemoglobinopathies | 1 | 2010 | 10 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 317 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2021 | 4212 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2010 | 72 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.090 |
Why?
|
| Carbon Monoxide | 1 | 2010 | 90 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 408 | 0.090 |
Why?
|
| STAT1 Transcription Factor | 1 | 2009 | 52 | 0.090 |
Why?
|
| Infant | 3 | 2021 | 3045 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2010 | 140 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 683 | 0.080 |
Why?
|
| Elbow | 1 | 2008 | 14 | 0.080 |
Why?
|
| Lifting | 1 | 2008 | 12 | 0.080 |
Why?
|
| Disease Progression | 1 | 2012 | 1531 | 0.080 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2020 | 23 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 639 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2021 | 751 | 0.070 |
Why?
|
| Folic Acid | 1 | 2007 | 60 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 421 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 2436 | 0.070 |
Why?
|
| Animals | 4 | 2020 | 26582 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 387 | 0.070 |
Why?
|
| Prognosis | 2 | 2012 | 3675 | 0.060 |
Why?
|
| Melanoma | 1 | 2008 | 454 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 2 | 2010 | 131 | 0.060 |
Why?
|
| Translating | 1 | 2023 | 18 | 0.060 |
Why?
|
| Cultural Competency | 1 | 2023 | 21 | 0.060 |
Why?
|
| Competency-Based Education | 1 | 2023 | 35 | 0.060 |
Why?
|
| Accreditation | 1 | 2023 | 60 | 0.050 |
Why?
|
| Peer Review | 1 | 2022 | 24 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1849 | 0.050 |
Why?
|
| Attitude | 1 | 2022 | 127 | 0.050 |
Why?
|
| Language | 1 | 2023 | 151 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2021 | 81 | 0.050 |
Why?
|
| Iron Overload | 1 | 2000 | 6 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2007 | 730 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 31 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 150 | 0.050 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 34 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 144 | 0.050 |
Why?
|
| Perception | 1 | 2021 | 168 | 0.050 |
Why?
|
| Uterus | 1 | 2021 | 215 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2007 | 711 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2020 | 173 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 62 | 0.040 |
Why?
|
| Personnel Delegation | 1 | 2019 | 1 | 0.040 |
Why?
|
| Iron | 1 | 2000 | 164 | 0.040 |
Why?
|
| Nigeria | 1 | 2020 | 152 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2019 | 37 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2020 | 194 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 90 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 97 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 116 | 0.040 |
Why?
|
| Risk Factors | 1 | 2008 | 5417 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 702 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 943 | 0.040 |
Why?
|
| Mitomycin | 1 | 2016 | 29 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2020 | 403 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1054 | 0.040 |
Why?
|
| Ilium | 1 | 2016 | 18 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2016 | 31 | 0.040 |
Why?
|
| Cochlea | 1 | 2016 | 50 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.040 |
Why?
|
| Neutropenia | 1 | 2016 | 215 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 288 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1577 | 0.030 |
Why?
|
| Apoptosis | 2 | 2014 | 1683 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 916 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 610 | 0.030 |
Why?
|
| Mastectomy | 1 | 2016 | 236 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 642 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1034 | 0.030 |
Why?
|
| DEAD Box Protein 58 | 1 | 2014 | 11 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1208 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2013 | 48 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 293 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1538 | 0.030 |
Why?
|
| Mice | 3 | 2014 | 11352 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2014 | 175 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1041 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2014 | 255 | 0.030 |
Why?
|
| Infrared Rays | 1 | 2010 | 17 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2010 | 11 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2014 | 374 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 83 | 0.020 |
Why?
|
| Thalassemia | 1 | 2010 | 16 | 0.020 |
Why?
|
| Breath Tests | 1 | 2010 | 55 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 384 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 94 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 305 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1924 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 458 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2009 | 103 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 391 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 790 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 557 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 295 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 379 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 736 | 0.020 |
Why?
|
| Micronucleus Tests | 1 | 2007 | 5 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 444 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1019 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1685 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1673 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 1056 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2007 | 464 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 1135 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2426 | 0.020 |
Why?
|
| Lung | 1 | 2009 | 1170 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 2378 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2007 | 669 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 3092 | 0.010 |
Why?
|
| Hemoglobin, Sickle | 1 | 2000 | 19 | 0.010 |
Why?
|
| Splenectomy | 1 | 2000 | 82 | 0.010 |
Why?
|
| Ferritins | 1 | 2000 | 29 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 3241 | 0.010 |
Why?
|
| Biopsy | 1 | 2000 | 1162 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 1230 | 0.010 |
Why?
|
| Biomarkers | 1 | 2000 | 1718 | 0.010 |
Why?
|